Heparin /certified fixed orthodontic courses by Indian dental academy


Published on

The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and offering a wide range of dental certified courses in different formats.

Indian dental academy provides dental crown & Bridge,rotary endodontics,fixed orthodontics,
Dental implants courses.for details pls visit www.indiandentalacademy.com ,or call

Published in: Education, Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Heparin /certified fixed orthodontic courses by Indian dental academy

  1. 1. Anticoagulant, Antithrombotic and Anti-Platelet Drugs www.indiandentalacademy.com
  2. 2. INDIAN DENTAL ACADEMY Leader in continuing dental education www.indiandentalacademy.com www.indiandentalacademy.com
  3. 3. Clinical Thrombosis • >2.5 million cases of deep venous thrombosis (DVT) per year • >600,000 cases of pulmonary embolism (PE) per year • >50,000 deaths per year from PE • PE contributes to another 150,000 deaths per year • > 11,000 postsurgical PE deaths per year www.indiandentalacademy.com
  4. 4. Indications For Antithrombotic Therapy • • • • Venous thromboembolic disease – Deep venous thrombosis (DVT) – Pulmonary embolism (PE) – Primary prophylaxis of DVT or PE Arterial thromboembolic disease • Prosthetic heart valves • Mitral valve disease, especially with atrial fibrillation • Congestive cardiomyopathies, especially with atrial fibrillatio • Atrial fibrillation • Mural cardiac thrombi • Transient ischemic attacks • Stroke in evolution Disseminated intravascular coagulation Maintenance of patency of vascular grafts, shunts, bypasses www.indiandentalacademy.com
  5. 5. www.indiandentalacademy.com
  6. 6. www.indiandentalacademy.com
  7. 7. www.indiandentalacademy.com
  8. 8. www.indiandentalacademy.com
  9. 9. www.indiandentalacademy.com
  10. 10. www.indiandentalacademy.com
  11. 11. www.indiandentalacademy.com
  12. 12. Recombinant Human Activated Protein C • Drotrecogin alfa (activated)- Xigris • Indicated for Severe Sepsis in Adults with Acute Organ Dysfunction with High Risk of Death • Reduction in Death as Primary End Point • Antithrombotic, Antiinfammatory, Profibrinolytic Properties • Serious Bleeding is Major Side Effect www.indiandentalacademy.com
  13. 13. www.indiandentalacademy.com
  14. 14. www.indiandentalacademy.com
  15. 15. www.indiandentalacademy.com
  16. 16. www.indiandentalacademy.com
  17. 17. www.indiandentalacademy.com
  18. 18. www.indiandentalacademy.com
  19. 19. www.indiandentalacademy.com
  20. 20. www.indiandentalacademy.com
  21. 21. Antithrombin III Inhibits the Following Serine Proteases • Coagulation • Fibrinolysis • • • • • • Plasmin Factor XIIa Factor XIa Factor IXa Factor Xa Thrombin Inhibitory activity against all these enzymes is substantially accelerated by heparin www.indiandentalacademy.com
  22. 22. Heparin • Heterogeneous; 3,000-30,000 d • Average=15,000 d (~45monosaccharide chains) • About 1/3 of dose binds to AT III • To form the AT III:Heparin:Clotting Factor Complex- requires at least 18 saccarides except • Unique high affinity pentasaccaride heparin sequences catalyze inhibition of Xa by AT www.indiandentalacademy.com
  23. 23. www.indiandentalacademy.com
  24. 24. Anticoagulant Properties of Heparin 1. Inhibits the thrombin-mediated conversion of fibrinogen to fibrin 2. Inhibits the aggregation of platelets by thrombin 3. Inhibits activation of fibrin stabilizing enzyme 4. Inhibits activated factors XII, XI, IX, X and II www.indiandentalacademy.com
  25. 25. Heparin • • • • • • • • Biologic Sources Bioavailability Metabolism Elimination Side Effects Overdose Contraindications Pregnancy- YES www.indiandentalacademy.com
  26. 26. www.indiandentalacademy.com
  27. 27. Unfractionated Heparin • High Dose – Treatment of venous/arterial thrombi – Requires monitoring – IV- 5,000 Units bolus, then 30,000-35,000 units/24 hrs – 80 Units/kg bolus, then 18 Units/kg/hr to maintain aPTT in therapeutic range www.indiandentalacademy.com
  28. 28. www.indiandentalacademy.com
  29. 29. Monitoring of Anticoagulant Therapy Heparin s.q. – no monitoring required i.v. - partial thromboplastin time (P.T.T.) *daily or more frequent if PTT varies mechanism – measures intrinsic pathway therapeutic goal – 2-2.5 times normal control value (-30 sec) www.indiandentalacademy.com
  30. 30. www.indiandentalacademy.com
  31. 31. Low Dose Unfractionated Heparin • Surgical Prophylaxis – 5,000 Units SQ 2 hr preop – 5,000 Units SQ every 12 hours • Medical Prophylaxis – 5,000 Units SQ every 12 hours • No monitoring required www.indiandentalacademy.com
  32. 32. www.indiandentalacademy.com
  33. 33. www.indiandentalacademy.com
  34. 34. www.indiandentalacademy.com
  35. 35. Indications for and Contraindications to Parenteral Anticoagulant Agents Anticoagulant Agent Class Approved & Appropriate Indications Contraindication Unfractionated heparin Antithrombin III inhibitor Treatment of venous thromboembolism or unstable angina; used when rapid reversal is important ? Prophylactic treatment Enoxaparin (Lovenox) Low-molecularweight heparin Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism or unstable angina Dalteparin (Fragmin) Low-molecularweight heparin Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism or unstable angina Regional anesthesia Low-molecularweight heparin Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism Regional anesthesia Tinzaparin (Innohep) www.indiandentalacademy.com Regional anesthesia Pregnancy Prosthetic Heart Valves
  36. 36. Indications for and Contraindications to Parenteral Anticoagulant Agents (cont’d) Ardeparin Low-molecular-weight heparin Approved; not being marketed Regional anesthesia Lepirudin Hirudin derivative Heparin-induced thrombocytopenia with thrombosis Thrombocytopenia other than heparin-induced thrombocytopenia Argatroban Direct thrombin inhibitor Heparin-induced thrombocytopenia with thrombosis Thrombocytopenia other than heparin-induced thrombocytopenia Danaparoid Heparinoid Prophylaxis against thrombosis in heparininduced thrombocytopenia Thrombocytopenia other than heparin-induced thrombocytopenia Bivalirudin Hirudin derivative Unstable angina or angioplasty Unknown Fondaparinux (Arixtra) Prophylaxis in highSynthetic factor Xa risk patients? inhibitor www.indiandentalacademy.com Unknown
  37. 37. www.indiandentalacademy.com
  38. 38. Heparin-Antibiotic Interactions • The second-generation cephalosporins- cefamandole, cefotetan, and cefoperazone, contain an Nmethylthiotetrazole (NMTT) side chain. This NMTT group can: • - Dissociate from the parent antibiotic in solution or in vivo and competitively inhibit vitamin K action, leading to prolongation of the prothrombin time and bleeding. • - This side chain is also associated with a disulfiram-like reaction to alcohol. • - Clinical bleeding has been less frequently reported with Cefotetan than with cefoperazone or cefamandole. www.indiandentalacademy.com
  39. 39. www.indiandentalacademy.com
  40. 40. Mechanisms of HIT • Type 1: In most of these cases, the fall in platelet count occurs within the first two days after heparin initiation, often returns to normal with continued heparin administration, and is of no clinical consequence. The mechanism of the thrombocytopenia is non-immune and appears to be due to a direct effect of heparin on platelet activation. • Type 2: Approximately 0.3 to 3 percent of patients receiving heparin develop an immune thrombocytopenia, mediated by antibodies to a heparin-platelet factor 4 complex. One study, for example, randomly assigned 665 patients to therapy with unfractionated heparin or LMW heparin. Type 2 HIT developed in 2.7 percent of patients treated with unfractionated heparin but in none of those receiving LMW heparin. www.indiandentalacademy.com
  41. 41. www.indiandentalacademy.com
  42. 42. Therapy of HIT • There are two recommended approaches: – Use of the heparinoid danaparoid – The direct thrombin inhibitor lepirudin (recombinant hirudin) – Based upon the data published to date, either danaparoid or lepirudin should be used to treat HIT that is complicated by thrombosis; these agents should also be considered for prophylactic therapy in patients with HIT without thrombosis until the platelet count has recovered www.indiandentalacademy.com
  43. 43. www.indiandentalacademy.com
  44. 44. www.indiandentalacademy.com
  45. 45. www.indiandentalacademy.com
  46. 46. www.indiandentalacademy.com
  47. 47. www.indiandentalacademy.com
  48. 48. www.indiandentalacademy.com
  49. 49. www.indiandentalacademy.com
  50. 50. Warfarin • • • • • • • • • • Bioavailability Metabolism Serum Protein Binding Vitamin K Status Protein C Effects Elimination Side Effects Overdose Contraindications Pregnancy- NO www.indiandentalacademy.com
  51. 51. www.indiandentalacademy.com
  52. 52. www.indiandentalacademy.com
  53. 53. www.indiandentalacademy.com
  54. 54. www.indiandentalacademy.com
  55. 55. www.indiandentalacademy.com
  56. 56. www.indiandentalacademy.com
  57. 57. www.indiandentalacademy.com
  58. 58. www.indiandentalacademy.com
  59. 59. www.indiandentalacademy.com
  60. 60. Contraindications to Antithrombotic Therapy • General risk factors -Pre-existing coagulation or platelet defect, thrombocytopenia, or other bleeding abnormality -Inaccessible ulcerative lesion (e.g., gastrointestinal tract lesion) -Central nervous system lesion (e.g., caused by stroke, surgery, trauma) -Spinal anesthesia or lumbar puncture -Malignant hypertension -Bacterial endocarditis -Advanced retinopathy -Old age (relative) -Aspirin or other antiplatelet drugs -Neoplastic disease www.indiandentalacademy.com
  61. 61. Contraindications to Antithrombotic Therapy • Specific to warfarin (ambulatory patients) -Early and late pregnancy -Poor patient cooperation, understanding, reliability -Unsatisfactory laboratory or patient follow-up -Occupational risk to trauma www.indiandentalacademy.com
  62. 62. Contraindications to Antithrombotic Therapy • Specific to thrombolytic agents -Recent thoracic, abdominal, or central nervous system surgery -Recent cerebrovascular accident, trauma, or neoplasm -Bleeding ulcer -Hypertension -Anticipated invasive procedures (arterial punctures, biopsies, central lines) -Concurrent hemostatic dysfunction www.indiandentalacademy.com
  63. 63. Platelet Receptor Mediated Pathways: Drugs Arachidonic Acid ASA NSAIDs ADP Ticlopidine Clopidogrel Thrombin -Final Common Pathway -Promotes Platelet Adhesion (Fibrinogen, vWF) GP IIB/IIIA Inhibitors Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban www.indiandentalacademy.com
  64. 64. Anti Platelet Drugs Drug Mechanism Uses Aspirin Permanently inhibits COX-1 and COX-2 CAD Stroke-TIAs NSAIDs Reversibly inhibits COX-1 Limited Dipyridamole Inhibits PDE; TIAs increases cAMP Ticlopidine Clopidrgrel Inhibits ADP TIAs;Stroke PlatAg;active CAD;PVD metabolite www.indiandentalacademy.com
  65. 65. Thank you www.indiandentalacademy.com Leader in continuing dental education www.indiandentalacademy.com